Ranitidine is a drug that has been manufactured, sold “over the counter” and prescribed by doctors, for heartburn acid reflux, and other digestive disorders to millions of Americans in 1983. The most common brand name for Ranitidine is Zantac. Zantac was produced by many drug companies such as Pfizer, GlaxoSmithKline, Sanofi, Boehringer, add more here with links
Zantac was first sold in the United States in 1983. By 1987, Zantac had become one of the most widely used drug on the market and was the first drug in the U.S. to top $1B in sales. In June 2019, a pharmaceutical testing lab found that Zantac and other generic versions of Ranitidine contained dangerously high levels of N-nitrosodimethylamine (NDMA). NDMA is highly toxic to humans, especially the liver, and has been conclusively linked to various forms of cancer since the 1970s. Dimethylhydrazine, which is the "D" in NDMA, is a component of rocket fuel. Recent testing reported that a single tablet of Zantac contained 26,000 times the acceptable daily limit of NDMA according to the FDA. These findings were reported to the FDA in June 2019. In fall 2019, the FDA issued a public safety warning on the medications containing Ranitidine. Voluntary recalls began and continued through the fall. The FDA did further testing and in April 2020, the FDA removed the product from the market. If you took Zantac and have been diagnosed with cancer, please complete the form to determine if you may be eligible for compensation. Contact us today.